Target intelligence / Profile preview

Mediator complex subunit 23 (MED23)

Target
MED23
Molecular classification
Transcriptional coactivator, Mediator complex subunit, Epigenetic regulator, Other
01

Overview

Mediator complex subunit 23 (MED23) is a large subunit of the Mediator multiprotein coactivator complex that acts as a critical regulator of transcription by RNA polymerase II in eukaryotes[1][4]. MED23 is part of the Tail module of the Mediator complex, and serves as a direct interface for multiple sequence-specific transcription factors—such as the MAPK-responsive factor Elk-1—thereby integrating extracellular and intracellular signaling information into gene-specific transcriptional responses[1][2][7][8]. The protein has a highly structured, arch-shaped conformation made up of multiple HEAT repeats organized into α-solenoids, facilitating broad protein–protein interactions, including with splicing factors like hnRNP L and epigenetic regulators such as the E3 ubiquitin ligase RNF20/40. Through these interactions, MED23 orchestrates processes ranging from histone modifications (notably, histone H2B mono-ubiquitination) to alternative mRNA splicing, connecting transcriptional activation with chromatin state and RNA metabolism[3][5][8]. Loss or aberrant function of MED23 impacts cell proliferation and differentiation, and aberrant upregulation is associated with tumorigenesis and cancer progression, particularly in lung tissue[3]. There are currently no approved therapeutic agents directly targeting MED23, but it is recognized as a functional and structurally druggable intersection in key gene regulation pathways.

Other names
MED23ARC130CRSP3DRIP130KIAA1216SUR2CRSP complex subunit 3hSur-2CRSP130CRSP133MRT18Activator-recruited cofactor 130 kDa componentCofactor required for Sp1 transcriptional activation subunit 3Protein sur-2 homologTranscriptional coactivator CRSP130Vitamin D3 receptor-interacting protein complex 130 kDa component
02

Mechanism of action

Not applicable; no clinically used drugs are directly targeting MED23, but it is a critical interaction point for transcription factor-mediated gene activation and epigenetic modulation

03

Biological functions

Regulation of gene transcription (RNA polymerase II-dependent)Integration of signal-dependent transcriptional activationCoupling of epigenetic histone modifications (H2B mono-ubiquitination)Regulation of alternative mRNA processing/splicingCell differentiationCell proliferation
04

Disease associations

Cancer (notably lung cancer, and involvement in tumorigenesis)Muscle differentiation/myogenesisPotential roles in developmental disordersOther
05

Safety considerations

Targeting MED23 may broadly disrupt gene expression, affecting basic cellular functions, development, or differentiation; concerns include on-target toxicity affecting multiple organ systems due to global transcriptional dysregulation[3]
06

Interacting drugs

None approved or in clinical use specifically targeting MED23 as of now (2025); research does not report direct-acting small molecule or biologic drugs
07

Biomarkers

Elevated MED23 and H2Bub (histone H2B mono-ubiquitination) levels may serve as biomarkers for certain cancer-related pathways, especially in human lung cancer[3]Null for patient selection or efficacy monitoring for any therapeutics at this time

Beyond the preview

Go deeper on Mediator complex subunit 23 (MED23).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mediator complex subunit 23 (MED23).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call